Innovent Biologics and Sanofi Announce License Deal for Drug Development in China
China-based biotech firm Innovent Biologics Inc. (HKG: 1801) and France’s Sanofi SA (NASDAQ: SNY) have...
China-based biotech firm Innovent Biologics Inc. (HKG: 1801) and France’s Sanofi SA (NASDAQ: SNY) have...
Innovent Biologics Inc. (HKG: 1801) released its Q2 2022 financial report, with product revenues exceeding...
China’s Innovent Biologics Inc. (HKG: 1801) and partner Laekna Therapeutics Shanghai Co., Ltd announced that...
Eli Lilly & Co. (NYSE: LLY) has secured special approval for its RET kinase inhibitor...
China-based Innovent Biologics Inc. (HKG: 1801) announced that its Phase II study of mazdutide (IBI362/OXM3)...
China-based Innovent Biologics Inc. (HKG: 1801) announced that the first prescription has been filled in...
China-based Innovent Biologics, Inc. (HKG: 1801) announced the successful first patient dosing in a Phase...
The National Medical Products Administration (NMPA) website indicates that China-based Innovent Biologics, Inc. (HKG: 1801)...
China-based Innovent Biologics Inc. (HKG: 1801) has announced receiving indication approvals from Indonesia’s Badan Pengawas...
China-based Innovent Biologics Inc. (HKG: 1801) has announced that a New Drug Application (NDA) filing...
Innovent Biologics (HKG: 1801), a prominent biotech firm headquartered in Suzhou, China, and Eli Lilly...